Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab.
Bibliographic Source(s)
National Institute for Health and Clinical Excellence (NICE). Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Oct. 42 p. (Technology appraisal guidance; no. 202).
Guideline Status
This is the current release of the guideline.
National Guideline Clearinghouse | Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab.: "Guideline Title
Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab.
Bibliographic Source(s) - Enviado mediante la barra Google"
No hay comentarios:
Publicar un comentario